世界の吸入麻酔薬市場 - 成長、動向、予測

高齢者人口の増加や、緊急処置が必要な事例の増加、入院日数の減少、医療サービスへのアクセス向上による手術件数の増加などによって、吸入麻酔薬の使用が増加しており、市場の成長が促されています。

当レポートでは、世界の吸入麻酔薬市場について調査し、市場の概要、タイプ・地域別の市場動向、市場規模の推移と予測、市場成長・阻害要因ならびに市場機会・課題の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

• 調査の成果
• 市場の定義
• 調査対象期間と予測
• 一般調査の前提条件
• レポートの概要

第2章 調査方法

• イントロダクション
• 分析方法
• 調査のタイムライン
• 調査のフェーズ
  • 2次調査
  • ディスカッションガイド
  • マーケットエンジニアリング＆計量経済学モデル

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要と産業動向

• 市場概況
• ファイブフォース分析
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係

第6章 市場力学

• 市場成長要因
  • 慢性疾患の発症率の高い高齢者人口の増加
  • 緊急処置が必要な事例の増加
  • 入院日数の減少に対する需要の高まり
  • 医療サービスへのアクセス向上による手術件数の増加
• 市場阻害要因
  • ほぼすべてのハロゲン化剤の一般的な競争
  • 最近の特許有効期限
• 市場機会
• 主な課題
  • 市場参入の高い障壁

第7章 世界の吸入麻酔薬市場：市場区分

• タイプ別
  • 亜酸化窒素（笑気ガス）
  • ハロゲン化剤

第8章 世界の吸入麻酔薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン・ポルトガル
  • スカンジナビア諸国
  • ベネルクス諸国
  • その他
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • オーストラリア・ニュージーランド
  • 韓国
  • その他
• 中東・アフリカ
  • 湾岸協力会議（CGG)
  • 南アフリカ
  • その他
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • その他

第9章 競合情勢

• M&A分析
• 新製品の発売
• 合意、コラボレーション、パートナーシップ

第10章 企業プロファイル

• Baxter
• Abbvie
• Piramal Healthcare
• Lunan Pharmaceuticals
• その他の企業

第11章 アナリストによる投資機会の見通し

第12章 市場の将来展望

The inhalation anesthetics market is expected to register a CAGR of 3.7% during the forecast period. The market is expected to grow due to the increase in the number of surgeries being performed, globally. For instance, according to the annual estimates of Sedana Medical, there were about 4.5-7.5 million people ventilated and sedated worldwide in 2017. Furthermore, a rise in population pool, an increase in the number of the geriatric population prone to chronic diseases, growing demand for a lesser duration of hospitalization, and increasing accessibility to health services are some of the other factors responsible for the growth of the inhalation anesthetics market.

Inhalation anesthetics are also majorly used for accident care, where the intravenous route of administration is not an easy task in ambulatory settings. In emergency labors, rapid sequence induction of general anesthesia is performed with intubation of the trachea. Therefore, the increasing number of emergency cases all over the world is driving the inhalation anesthetics market.

As per the UN reports, the global population aged 60 years or over numbered 962 million in 2017, more than twice as large as in 1980, when there were 382 million older people worldwide. The number of older people is expected to double by 2050, projected to reach nearly 2.1 billion. However, side effects associated with the inhalation anesthetics, the lower adoption rate in case of inhaled anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents, and recent patent expiries are restraining the inhalation anesthetics market.

Key Market Trends

Sevoflurane Holds the Major Share in the Inhalation Anesthetics Market

Sevoflurane is the most widely used inhalational anesthetic, owing to its therapeutic advantages and low cost. Sevoflurane is an ether inhalation anesthetic agent with low pungency, a non-irritant odor, and a low blood, gas partition coefficient. It is found to be ideal for asthma patients or people with sensitized air passages. The drug has captured a major portion of the market, and it is expected to retain its position in the future as well.

The product is also marketed under the following names, Sojourn, Ultane, and Ultane PEN, in the United States, with Ultane being the most popular among all age groups. AbbVie is a key player of the market studied, and it sells Sevoflurane (sold under the trademarks Ultane and Sevorane) worldwide for human use.

Asia-Pacific is Expected to be the Fastest Growing Market

Asia-Pacific is expected to expand at the fastest CAGR over the forecast period. The key factors contributing to its rapid growth include increasing population, public and private healthcare expenditure, availability of healthcare insurance for masses, and incidence of chronic diseases. Asia-Pacific is anticipated to have a significant growth due to the presence of high unmet needs, an increase in health awareness, a large population base, and an increase in the number of surgeries. Moreover, propelling medical tourism due to the availability of cost-efficient and advanced healthcare treatment options, compared to the other geographical regions, and increasing adoption of novel technologies are bolstering the growth of the inhalational anesthetics market in Asia-Pacific.

North America also witnessed a rapid increase in the number of diseases, such as obesity, cardiovascular disease, and different types of cancers, which contributed to the growth of the inhalation anesthetics market in the region.

Competitive Landscape

Market players in the inhalation anesthetics market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. Only a few companies are coming forward with innovative technologies and new product launches. For example, in January 2019, Sandoz, a Novartis division, launched Desflurane Liquid for Inhalation, the first generic of Suprane, in the United States, as an inhalation agent for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for the maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Geriatric Population Prone to Chronic Diseases
  • 4.2.2 Increasing Number of Emergency Cases and Surgical Interventions
  • 4.2.3 Growing Demand for Lesser Duration in Hospitalization
  • 4.2.4 Increasing Accessibility to Health Services and Surgeries
• 4.3 Market Restraints
  • 4.3.1 Generic Competition for Almost All Halogenated Agents
  • 4.3.2 Side-effects of Inhaler Anesthesia Drugs
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 Type
  • 5.1.1 Desflurane
  • 5.1.2 Sevoflurane
  • 5.1.3 Isoflurane
  • 5.1.4 Other Types
• 5.2 End User
  • 5.2.1 Hospitals
  • 5.2.2 Ambulatory Surgical Centers
  • 5.2.3 Other End Users
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 AbbVie Inc.
  • 6.1.2 Merck KGaA
  • 6.1.3 Baxter International Inc.
  • 6.1.4 Fresenius Kabi AG
  • 6.1.5 Halocarbon Products Corporation
  • 6.1.6 Hikma Pharmaceuticals PLC
  • 6.1.7 Jiangsu Hengrui Medicine Co. Ltd
  • 6.1.8 Lunan Pharmaceutical Group Co. Ltd
  • 6.1.9 Piramal Enterprises Limited
  • 6.1.10 Troikaa Pharmaceuticals Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS